{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Razaxaban (also known as BMS-561389 or DPC 906) is an oral factor Xa inhibitor that was being developed for the treatment of thrombosis. It showed excellent results in the lab for efficacy and bioavailability and was therefore selected for further development. In a phase 1 clinical trial with healthy subjects, Razaxaban was well tolerated with minor bleeding. However, higher bleeding was reported in thrombosis patients in a phase 2 clinical trial, and the development of this drug was therefore discontinued in 2005.
Status:
Investigational
Source:
NCT00003403: Phase 1 Interventional Completed Unspecified Adult Solid Tumor, Protocol Specific
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
13-deoxyadriamycin hydrochloride (13-Deoxydoxorubicin hydrochloride, GPX-100) is an anthracycline similar to doxorubicin. GPX-100 is unique among anthracyclines because it is not converted to doxorubicinol during metabolism in the body. This metabolite has been shown to be a major cause of damage to the heart (cardiotoxicity) in laboratory studies. GPX-100 belongs to the class of reactive oxygen species stimulants; RNA synthesis inhibitors and Type II DNA topoisomerase inhibitors. It was in phase II clinical trial for the treatment of cancer.
Status:
Investigational
Source:
INN:salclobuzic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Salclobuzate sodium was developed as an oral absorption promoter. This compound had to “chaperone” poorly permeable payloads across the intestine. Information about the current use of this compound is not available.
Status:
Investigational
Source:
USAN:DITIOCADE SODIUM [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ACHIRAL)
Phenamazoline is an antazoline derivative. It is a sympathomimetic agent. It was developed as vasoconstrictor but its carbon analog is a vasodilator.
Status:
Investigational
Source:
INN:mazapertine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Mazapertine (RWJ-37796) is an arylpiperazine antipsychotic with high affinity to dopamine D2 and D3, serotonin 5-HT1A and alpha 1A-adrenergic receptors. It was being studied in the treatment of schizophrenia.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Napitane [A 75200, ABT 200] is a norepinephrine uptake inhibitor and α2 adrenoceptor antagonist. It was undergoing clinical trials with Abbott in the USA as a treatment for depression. However it was discontinued later. Napitane is a potent alpha 2-adrenoceptor antagonist (Ki = 1.2 nM) with modest norepinephrine uptake-blocking activity (IC50 = 841 nM).
Status:
Investigational
Source:
NCT04187144: Phase 3 Interventional Completed Urinary Tract Infections
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Gepotidacin (formerly GSK2140944) is a novel, first-in-class, triazaacenaphthylene antibacterial that selectively inhibits bacterial DNA gyrase and topoisomerase IV by a unique mechanism, one that is not utilized by any currently approved human therapeutic agent. As a consequence of its novel mode of action, gepotidacin is active in vitro against target pathogens carrying resistance determinants to established antibacterials, including fluoroquinolones. Gepotidacin has demonstrated in vitro activity against key pathogens, including drug-resistant strains, associated with a range of conventional and biothreat infections. GlaxoSmithKline is developing Gepotidacin for the treatment of gonorrhoea and skin and soft tissue infections.
Status:
Investigational
Source:
INN:eprociclovir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Eprociclovir (A5021, 9-[[cis-1', 2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine) is a nucleoside analog with antiviral activity. Antiviral activity of eprociclovir appears to depend rapid and stable accumulation of its triphosphate in infected cells and on inhibition of viral DNA polymerase by its triphosphate. Eprociclovir was shown to be a potent inhibitor of the replication of herpes simplex virus type 1, 2, 6, Epstein-Barr virus and varicella zoster virus, both in vitro and in vivo.
Eprociclovir development has been discontinued.
Status:
Investigational
Source:
NCT00358488: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Milveterol (also known as GSK159797) was developed as a longer-acting beta2 adrenoceptor agonist for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Milveterol completed phase II clinical trials for asthmatic subjects. However further development of the drug was discontinued.
